Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» blood cancer
blood cancer
FDA to delay decision on Bristol Myers-2seventy bio cancer therapy
FDA to delay decision on Bristol Myers-2seventy bio cancer therapy
Reuters
Bristol Myers Squibb
2seventy bio
blood cancer
FDA
Abecma
Flag link:
Bristol Myers pays $100M for a different kind of ADC
Bristol Myers pays $100M for a different kind of ADC
BioPharma Dive
Bristol Myers Squibb
antibody-drug conjugate
bone cancer
blood cancer
Orum Therapeutics
Flag link:
ALX follows Gilead in axing CD47 blood cancer trials as data disappoint
ALX follows Gilead in axing CD47 blood cancer trials as data disappoint
Fierce Biotech
Gilead Sciences
ALX Oncology
blood cancer
clinical trials
anti-CD47
evorpacept
Flag link:
Amgen granted full FDA approval for blood cancer treatment
Amgen granted full FDA approval for blood cancer treatment
Biopharma Reporter
Amgen
Blincyto
FDA
blood cancer
Flag link:
Roche follows AbbVie with FDA approval for dual-targeting lymphoma drug
Roche follows AbbVie with FDA approval for dual-targeting lymphoma drug
BioPharma Dive
Roche
Columvi
FDA
relapsed or refractory diffuse large B-cell lymphoma
blood cancer
Flag link:
FDA delays approval decision on GSK's $1.9B blood cancer bet
FDA delays approval decision on GSK's $1.9B blood cancer bet
Fierce Biotech
GSK
FDA
momelotinib
blood cancer
Flag link:
AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up
AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up
Fierce Pharma
AbbVie
Pharmacyclics
BeiGene
Brukinsa
patents
Imbruvica
blood cancer
Flag link:
Foghorn finally has clear route back to clinic after FDA lifts yearlong hold on blood cancer drug
Foghorn finally has clear route back to clinic after FDA lifts yearlong hold on blood cancer drug
Fierce Biotech
Foghorn Therapeutics
FHD-286
FDA
blood cancer
Flag link:
Allogeneic cell therapy approval to pave the way for future therapies in this class
Allogeneic cell therapy approval to pave the way for future therapies in this class
Clinical Trials Arena
Gamida Cell
stem cell transplant
Omisirge
blood cancer
FDA
Flag link:
FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market
FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market
Fierce Biotech
Daiichi Sankyo
Astellas
Novartis
quizartinib
FDA
blood cancer
Flag link:
After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE
After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE
Fierce Pharma
Gilead Sciences
CAR-T
Yescarta
UK
NICE
Kite Pharma
Novartis
blood cancer
Flag link:
With new data, Nkarta builds case for ‘natural killer’ cell therapy
With new data, Nkarta builds case for ‘natural killer’ cell therapy
BioPharma Dive
Nkarta Therapeutics
cancer
blood cancer
natural killer cell therapies
NKX019
Flag link:
Jazz plays coda to blood cancer approval, securing FDA nod for revised dosing schedule
Jazz plays coda to blood cancer approval, securing FDA nod for revised dosing schedule
Fierce Pharma
Jazz Pharmaceuticals
FDA
Rylaze
blood cancer
acute lymphoblastic leukemia
lymphoblastic lymphoma
Flag link:
GSK to pull blood cancer drug from US market after study failure
GSK to pull blood cancer drug from US market after study failure
BioPharma Dive
GSK
blood cancer
Blenrep
clinical trials
Multiple Myeloma
Flag link:
Merck & Co. inks $1.4B blood cancer biotech buyout to muscle in on Bristol Myers, Novartis
Merck & Co. inks $1.4B blood cancer biotech buyout to muscle in on Bristol Myers, Novartis
Fierce Biotech
Merck
M&A
Imago BioSciences
blood cancer
Flag link:
After chat with FDA, ImmunoGen delays pivotal top-line data on blood cancer ADC to 2024
After chat with FDA, ImmunoGen delays pivotal top-line data on blood cancer ADC to 2024
Fierce Biotech
Immunogen
antibody drug conjugate
pivekimab sunirine
blood cancer
Flag link:
Novartis suspends platform trial, advancement shot of four blood cancer assets drop
Novartis suspends platform trial, advancement shot of four blood cancer assets drop
Clinical Trials Arena
Novartis
clinical trials
blood cancer
tuberculosis
uterine leiomyoma
Flag link:
AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark
AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark
Fierce Biotech
AACR
AbbVie
navitoclax
myelofibrosis
blood cancer
Flag link:
ASH: Roche uncorks eyepopping responses in bispecific test, hoping to add a jewel to its future portfolio
ASH: Roche uncorks eyepopping responses in bispecific test, hoping to add a jewel to its future portfolio
Endpoints
ASH2021
Roche
Genentech
bispecific antibodies
blood cancer
mosunetuzumab
Flag link:
Mei, with Bayer and Gilead in its sights, posts pivotal data on blood cancer prospect
Mei, with Bayer and Gilead in its sights, posts pivotal data on blood cancer prospect
Fierce Biotech
MEI Pharma
blood cancer
follicular lymphoma
zandelisib
Bayer
Gilead Sciences
Flag link:
Pages
1
2
3
next ›
last »